CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
Necitumumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02392507
NCT02392507Phase 2Completed
CompareCT.gov

A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company·interventional·Posted Mar 19, 2015·Updated Nov 19, 2020

In Brief

A Phase 2 clinical trial evaluating Necitumumab, Nab-Paclitaxel, and 1 other intervention for Carcinoma, Non-Small Cell Lung Cancer (NSCLC). Completed, enrolled 54 participants across 1 site.

Detailed Summary

The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small Cell Lung Cancer (NSCLC)
CountriesUnited States
CollaboratorsCelgene

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 19, 2015
Enrollment StartOct 12, 2015
Primary CompletionJan 29, 2018
Study CompletionNov 6, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.3 years ago

Interventions

Necitumumabdrug

Administered IV

Nab-Paclitaxeldrug

Administered IV

Carboplatindrug

Administered IV